Is Bliss GVS Pharma Ltd debt-free?

Yes, Bliss GVS Pharma Ltd is debt-free with a debt-to-equity ratio of 0.06.

Home

Bliss GVS Pharma Ltd

Bliss GVS Pharma Ltd Financials

Bliss GVS Pharma Ltd Financial Statement

Bliss GVS Pharma Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars	Mar 2025	Dec 2024	Sep 2024
Revenue	165.36	191.25	191
Operating Expense	142.27	153.86	157.27
Net Profit	11.45	21.05	17.04
Net Profit Margin	6.92	11.01	8.92
Earning Per Share	1.08	2	1.63
EBIDTA	24.13	38.95	35.62
Effective Tax Rate	17.11	27.46	25.91

Particulars	Mar 2025
Revenue	165.36
Operating Expense	142.27
Net Profit	11.45
Net Profit Margin	6.92
Earning Per Share	1.08
EBIDTA	24.13
Effective Tax Rate	17.11

Bliss GVS Pharma Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars	Mar 2025	Mar 2024	Mar 2023
Total Revenue Annual	667.20	605.46	598.34
Operating Expenses Annual	575.62	498.29	508.18
Operating Profit Annual	127.80	99.58	140.92
Interest Annual	6.58	5.81	10.06
Depreciation	27.05	23.52	15.17
Net Profit Annual	68.97	50.64	85.48
Tax Annual	25.20	19.61	30.21

Particulars	Mar 2025
Total Revenue Annual	667.20
Operating Expenses Annual	575.62
Operating Profit Annual	127.80
Interest Annual	6.58
Depreciation	27.05
Net Profit Annual	68.97
Tax Annual	25.20

Bliss GVS Pharma Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars	Mar 2025	Mar 2024	Mar 2023
Cash Flow at the Beginning	14.17	18.60	13.82
Cash Flow from Operations	97.21	82.17	43.81
Cash Flow from Investing	-77.73	-65.84	-12.97
Cash Flow from Financing	-26.71	-20.76	-26.05
Cash Flow at the End	6.95	14.17	18.60

Particulars	Mar 2025
Cash Flow at the Beginning	14.17
Cash Flow from Operations	97.21
Cash Flow from Investing	-77.73
Cash Flow from Financing	-26.71
Cash Flow at the End	6.95

Bliss GVS Pharma Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars	Mar 2025	Mar 2024	Mar 2023
PBDIT Margin (%)	19.15	23.18	23.55
PBIT Margin (%)	15.10	19.29	21.02
PBT Margin (%)	12.81	15.97	18.93
Net PROFIT Margin (%)	10.34	8.36	14.29
Return On Networth / Equity (%)	6.74	7.91	9.56
Return On Networth /Employed (%)	9.16	11.18	12.81
Return On Assets (%)	6.31	4.85	8.71
Total Debt / Equity (X)	0.07	0.08	0.10
Asset Turnover Ratio (%)	0.61	0.58	0.61

Particulars	Mar 2025
PBDIT Margin (%)	19.15
PBIT Margin (%)	15.10
PBT Margin (%)	12.81
Net PROFIT Margin (%)	10.34
Return On Networth / Equity (%)	6.74
Return On Networth /Employed (%)	9.16
Return On Assets (%)	6.31
Total Debt / Equity (X)	0.07
Asset Turnover Ratio (%)	0.61

Bliss GVS Pharma Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars	Mar 2025	Mar 2024	Mar 2023
Fixed Assets Annual	367.89	329.95	324.82
Total Current Assets Annual	767.69	772.23	729.65
Non Current Assets Annual	452.01	378.04	410.04
Total Shareholders Funds Annual	1,058.63	988.44	937.00
Total Assets Annual	1,219.70	1,150.27	1,139.69

Particulars	Mar 2025
Fixed Assets Annual	367.89
Total Current Assets Annual	767.69
Non Current Assets Annual	452.01
Total Shareholders Funds Annual	1,058.63
Total Assets Annual	1,219.70

Bliss GVS Pharma Ltd Earning Calls

EPS (INR)

Expected

1.47

Reported

1.47

Surprise

0.00%

Dec 2024

EPS beaten by 0.00%

Sep 2024

EPS beaten by 0.44%

Jun 2024

EPS beaten by 0.00%

Dividend Pages

PE Ratio

FAQS on Bliss GVS Pharma Ltd Financials

As of Jul 20, 2025, Bliss GVS Pharma Ltd has a market capitalization of 1,238.63 Cr. Value Research classifies it as a Small-Cap company.

Yes, Bliss GVS Pharma Ltd is with a debt-to-equity ratio of 0.06.

In FY 2024 , Bliss GVS Pharma Ltd recorded a total revenue of approximately 667.20 Cr marking a significant milestone in the company's financial performance.

Bliss GVS Pharma Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately 0.3% and 0.1% annually, respectively..

Bliss GVS Pharma Ltd's current PE ratio is 17.96.

Bliss GVS Pharma Ltd's ROCE averaged 10.8% from the FY ending March 2023 to 2025, with a median of 11.0%. It peaked at 12.4% in March 2023, reflecting strong capital efficiency over the period..

Bliss GVS Pharma Ltd's latest EBIT is Rs. 100.75 Cr, surpassing the average EBIT of Rs. 100.86 Cr over the 5 years..